Pfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech Stock

14
5
Favorite

Pfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech Stock

Jason Hawthorne2021-04-07

Developing a vaccine to combat the SARS-CoV-2 virus was no small feat. Previously, the fastest vaccine ever developed took four years. Beginning in less than one year from initial development, people ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

oyxeena
·2021-04-07
Erm...
Reply
2
Report
cyong
·2021-04-07
wow crazy
Reply
Like
Report
dontlose
·2021-04-07
This stock should be at 50$ its waiting to zoom
Reply
1
Report
Fold Replies
- 木吉蒂:
  Let's see how they perform after they report their results around 4-May. Their Covid-19 vaccine partner, Biotech already announced a good set of results (but they're a small co vs PFE)
  2021-04-07
  Reply
  Report
Didilai
·2021-04-07
Wow crazy
Reply
1
Report
Foros
·2021-04-07
Big nuts
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2125791090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-07 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2125791090","market":"us","top_or_hot":-1,"title":"Pfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech Stock","media":"Jason Hawthorne","content":"<div>\n<p>Developing a vaccine to combat the SARS-CoV-2 virus was no small feat. Previously, the fastest vaccine ever developed took four years. Beginning in less than one year from initial development, people ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/06/pfizers-ceo-makes-a-claim-that-might-shock-anyone/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-07 10:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/06/pfizers-ceo-makes-a-claim-that-might-shock-anyone/><strong>Jason Hawthorne</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Developing a vaccine to combat the SARS-CoV-2 virus was no small feat. Previously, the fastest vaccine ever developed took four years. Beginning in less than one year from initial development, people ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/06/pfizers-ceo-makes-a-claim-that-might-shock-anyone/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/06/pfizers-ceo-makes-a-claim-that-might-shock-anyone/","article_id":"2125791090","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2125791090","pubTimestamp":1617760800,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The leading developers of mRNA drugs hope the claim turns out to be foolish.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞首席执行官的这一言论可能会让任何持有Moderna或BioNTech股票的人感到震惊","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"Developing a vaccine to combat the SARS-CoV-2 virus was no small feat. Previously, the fastest vaccine ever developed took four years. Beginning in less than one year from initial development, people around the world are being inoculated with mRNA that hijacks the protein-building instructions cells use for nearly every bodily function.\nTwo of 2020's heroes, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), have been working with the technology for more than a decade. A year after partnering with one of them, Pfizer's (NYSE:PFE) CEO thinks his company has it all figured out and is ready to go it alone. It's a bold claim -- but what if he's right?\nA short history of messenger RNA\nDNA stores the instructions cells use to make proteins.  Messenger RNA (mRNA) is just as important: It carries the genetic code from the DNA to the protein-making machinery. Despite being relatively easy to produce, no mRNA vaccine had ever won approval prior to the COVID pandemic. When research began in the 1990s, it was considered too outlandish to gain any support or funding. In fact, Katalin Kariko, the researcher who finally cracked the code, was demoted at the University of Pennsylvania for her lack of progress.\nDespite her theory making biological sense, the immune system would quickly destroy any synthetic RNA it found. Ten years after her demotion, Kariko solved the mystery and published a series of papers. That research caught the eye of at least two scientists, the ones who would go on to found Moderna and BioNTech.\nFast-forward to 2021, and those companies have multiple drug candidates in their respective pipelines to fight viral illnesses, cancer, and other diseases. Moderna has 27 candidates at some stage of clinical development while BioNTech has 22. Of course, both also now have authorized vaccines for COVID-19.\nA bold claim\nYou might think a decade of work and portfolio of drug candidates would offer some protection against rivals. You might also expect that strategic partners might recognize the expertise required in developing those pipelines. If you do, Pfizer's CEO Albert Bourla thinks you're wrong.\nBourla recently discussed his company's experience as BioNTech's partner on Comirnaty, their joint COVID-19 vaccine. He claimed the past year has given his company a decade's worth of experience. He also believes Pfizer is now the leading mRNA company and doesn't want to lose its advantage. He said his company will be hiring staff and leveraging the new mRNA manufacturing network it developed last year. Despite stating that he liked working with BioNTech, he was clear he didn't think the partnership was necessary, saying: \"We have developed our own expertise.\"\nWhat this means for investors in BioNTech and Moderna\nEven if Pfizer succeeds on its own, the market for biotechnology is large enough to support many winners. Case in point, Pfizer is already partnering with BioNTech on a vaccine for influenza, a $5 billion market. The company also anticipates producing Comirnaty for several years, with analysts predicting $10 billion in sales next year and $2.4 billion in 2025. With a 50-50 split of the profits, that gives each partner plenty of capital to support its trials in multiple diseases.\nPfizer might have built out an impressive network of mRNA manufacturing and logistics in 2020, but scientifically its last year was a bust. Ibrance, its key breast cancer drug, failed its attempt to become an early-stage treatment. Its arthritis medicine, Xeljanz, showed an increased risk of heart attack and cancer compared to alternative treatments.\nThis means there are two smaller, more nimble biotechs at the forefront of a new industry. Pfizer will no doubt be a formidable competitor: Any $200 billion company would be when it decides to do something new. However, it is a stodgy old pharmaceutical giant with a lot of money but a spotty recent track record. It's trying to transform, but there isn't a lot of proof yet.\nFor shareholders of Moderna and BioNTech, Pfizer's claim validates how large the opportunity must be. The two upstarts will likely continue producing innovations, and Pfizer will likely make contributions in the field of mRNA. It's just that those contributions are more likely to be based on the manufacturing network it has established than on scientific discovery. Until Pfizer proves it can go it alone, Wall Street will likely continue betting on the companies with the intellectual property. Investors who want exposure to the future of mRNA probably should too.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":341049858,"gmtCreate":1617764709374,"gmtModify":1704702828324,"author":{"id":"3579000653896843","authorId":"3579000653896843","name":"oyxeena","avatar":"https://static.tigerbbs.com/a5cad07249c27a5d870e20f6c23c58b9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579000653896843","authorIdStr":"3579000653896843"},"htmlText":"Erm...&nbsp;","listText":"Erm...&nbsp;","text":"Erm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341049858","repostId":2125791090,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":341054791,"gmtCreate":1617764491613,"gmtModify":1704702824439,"author":{"id":"3568946367701965","authorId":"3568946367701965","name":"cyong","avatar":"https://static.tigerbbs.com/8575f448e784d75d9b7341464aa54fd8","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"3568946367701965","authorIdStr":"3568946367701965"},"htmlText":"wow crazy","listText":"wow crazy","text":"wow crazy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341054791","repostId":2125791090,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":341024122,"gmtCreate":1617763598366,"gmtModify":1704702808394,"author":{"id":"3578390540207500","authorId":"3578390540207500","name":"dontlose","avatar":"https://static.tigerbbs.com/83dae59fdfe891a662b9f6cf00aeefbb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3578390540207500","authorIdStr":"3578390540207500"},"htmlText":"This stock should be at 50$ its waiting to zoom","listText":"This stock should be at 50$ its waiting to zoom","text":"This stock should be at 50$ its waiting to zoom","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/341024122","repostId":2125791090,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3976225,"gmtCreate":1617767649477,"gmtModify":1680783147132,"authorId":3577229760496516,"author":{"id":3577229760496516,"idStr":"3577229760496516","authorId":3577229760496516,"name":"木吉蒂","avatar":"https://static.tigerbbs.com/89290f2c42589f1e42296c61dde71238","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.22","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":341024122,"type":1,"supId":0,"prevId":0,"content":"Let's see how they perform after they report their results around 4-May. Their Covid-19 vaccine partner, Biotech already announced a good set of results (but they're a small co vs PFE)","text":"Let's see how they perform after they report their results around 4-May. Their Covid-19 vaccine partner, Biotech already announced a good set of results (but they're a small co vs PFE)","html":"Let's see how they perform after they report their results around 4-May. Their Covid-19 vaccine partner, Biotech already announced a good set of results (but they're a small co vs PFE)"}],"langContent":"EN"},{"id":341021865,"gmtCreate":1617763221557,"gmtModify":1704702801167,"author":{"id":"3579091077947115","authorId":"3579091077947115","name":"Didilai","avatar":"https://static.tigerbbs.com/7c36c3a0e5eed09ce50765877a8f373c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579091077947115","authorIdStr":"3579091077947115"},"htmlText":"Wow crazy","listText":"Wow crazy","text":"Wow crazy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341021865","repostId":2125791090,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":341062180,"gmtCreate":1617762721040,"gmtModify":1704702790646,"author":{"id":"3574156765565189","authorId":"3574156765565189","name":"Foros","avatar":"https://static.tigerbbs.com/4aab8cbc5838ac3992a3d449f933303e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574156765565189","authorIdStr":"3574156765565189"},"htmlText":"Big nuts&nbsp;","listText":"Big nuts&nbsp;","text":"Big nuts","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341062180","repostId":2125791090,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":14,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}